login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
All US stocks
All Canadian stocks
All European stocks
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Account
Disclaimer
Affiliate
Contact
Privacy
KALVISTA PHARMACEUTICALS INC (KALV) Stock News
NASDAQ:KALV - Nasdaq -
US4834971032
-
Common Stock
- Currency: USD
15.76
-0.05 (-0.32%)
Summary
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
KALV Latest News, Press Relases and Analysis
All
Press Releases
8 days ago - By: KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals Announces UK MHRA Approval of EKTERLY® (sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema
9 days ago - By: Benzinga
- Mentions:
CVM
AAPL
GILT
RARE
...
Ultragenyx Pharmaceutical, Apple And Other Big Stocks Moving Lower In Monday's Pre-Market Session
13 days ago - By: KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals Provides Operational Update and Fiscal Year 2025 Financial Results
14 days ago - By: Yahoo Finance
- Mentions:
VZ
KalVista price target raised to $37 from $22 at BofA
15 days ago - By: Benzinga
- Mentions:
KLAC
ABT
DHR
GS
...
Meta Platforms To Rally Around 9%? Here Are 10 Top Analyst Forecasts For Tuesday
16 days ago - By: Investor's Business Daily
KalVista Ends Its Unexpectedly Messy Path To Approval In HAE Treatment
16 days ago - By: Bloomberg
KalVista Shares Surge as FDA Approves New Drug After Delay
16 days ago - By: KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals Announces FDA Approval of EKTERLY® (sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema
21 days ago - By: KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
a month ago - By: KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals Enters into Licensing Agreement with Pendopharm to Commercialize Sebetralstat for HAE in Canada
a month ago - By: Investor's Business Daily
- Mentions:
GSK
How KalVista Pharma Is Taking On A Rare But Deadly Disease
a month ago - By: KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals Presents New Data at the European Academy of Allergy and Clinical Immunology Congress 2025 on the Efficacy of Sebetralstat for the On-demand Treatment of HAE Attacks Among Patients Receiving Long-Term Prophylaxis
a month ago - By: Bloomberg
FDA Tells Drugmaker ‘Heavy Workload’ to Delay Approval Decision
a month ago - By: KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals Announces FDA Will Not Meet PDUFA Goal Date for Sebetralstat NDA for Hereditary Angioedema Due to FDA Resource Constraints
2 months ago - By: KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals to Present New Sebetralstat Data at the European Academy of Allergy and Clinical Immunology Congress 2025
2 months ago - By: KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2 months ago - By: KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals Medical Congress Presentations Highlight Potential of Sebetralstat to Redefine Hereditary Angioedema Management
2 months ago - By: KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
2 months ago - By: KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals to Present New Sebetralstat Data With 10 Abstracts Accepted at Upcoming Medical Meetings
3 months ago - By: KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3 months ago - By: KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals to Present at the Citizens Life Sciences Conference
4 months ago - By: Yahoo Finance
- Mentions:
TSLA
LVO
LiveOne reports preliminary FY25 revenue $112M+, consensus $118.08M
4 months ago - By: KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals Enters Into Licensing Agreement With Kaken Pharmaceutical to Commercialize Sebetralstat for HAE in Japan
4 months ago - By: KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
4 months ago - By: KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals to Present at 24th Annual Needham Virtual Healthcare Conference
4 months ago - By: KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals Announces Early Completion of Enrollment in KONFIDENT-KID Pediatric HAE Trial
4 months ago - By: KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update
5 months ago - By: KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals to Host Investor Webcast Highlighting Commercialization Strategy, Plans and Progress for Sebetralstat in Hereditary Angioedema
5 months ago - By: KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
5 months ago - By: KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals Shares Latest Sebetralstat Findings at the American Academy of Allergy, Asthma & Immunology 2025 Annual Meeting
Please enable JavaScript to continue using this application.